Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP1A | P62942 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.34 |
| ▸ | MAPT | P10636 | 3/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 4/20 | 0.33 |
| ▸ | CA2 | P00918 | 4/20 | 0.33 |
| ▸ | CA12 | O43570 | 3/20 | 0.33 |
| ▸ | CA9 | Q16790 | 3/20 | 0.33 |
| ▸ | CACNA1A | O00555 | 1/20 | 0.33 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.33 |
| ▸ | CACNB1 | Q02641 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13920516 | 0.84 | ATM (0.41) | FKBP1AKMT2AMEN1ALDH1A1MAPT | |
| SCHEMBL12705544 | 0.84 | ATM (0.41) | FKBP1AKMT2AMEN1ALDH1A1MAPT | |
| SCHEMBL12705543 | 0.83 | ANPEP (0.50) | FKBP1AKMT2AMEN1ALDH1A1MAPT | |
| SCHEMBL9636968 | 0.79 | FKBP1A (0.39) | FKBP1AKMT2AMEN1ALDH1A1MAPT | |
| SCHEMBL7728453 | 0.79 | FKBP1A (0.39) | FKBP1AKMT2AMEN1ALDH1A1MAPT | |
| SCHEMBL7728457 | 0.79 | FKBP1A (0.39) | FKBP1AKMT2AMEN1ALDH1A1MAPT | |
| SCHEMBL14278562 | 0.76 | MMP2 (0.56) | FKBP1AKMT2AMEN1 | |
| SCHEMBL12705542 | 0.75 | SMYD3 (0.39) | KMT2AMEN1ALDH1A1MAPT | |
| SCHEMBL13920578 | 0.73 | KMT2A (0.34) | FKBP1AKMT2AMEN1ALDH1A1MAPT | |
| SCHEMBL11195762 | 0.70 | FKBP1A (0.42) | FKBP1AKMT2AMEN1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7919505-B2 | Xinafoate salt of a substituted 5-oxazol-2-yl-quinoline compound | SCHERING CORPORATION (US) | 2011-04-05 | — | — | US | disclosed |
| US-20080027101-A1 | XINAFOATE SALT OF A SUBSTITUTED 5-OXAZOL-2-YL-QUINOLINE COMPOUND | SCHERING CORPORATION | 2008-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027101-A1 | XINAFOATE SALT OF A SUBSTITUTED 5-OXAZOL-2-YL-QUINOLINE COMPOUND | XDH, UPF1, NOX5 | FKBP1A 2459/4885KMT2A 2590/4885MEN1 4654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.